» Articles » PMID: 21045812

Surface Characteristics of Nanoparticles Determine Their Intracellular Fate in and Processing by Human Blood-brain Barrier Endothelial Cells in Vitro

Overview
Journal Mol Ther
Publisher Cell Press
Date 2010 Nov 4
PMID 21045812
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

A polarized layer of endothelial cells that comprises the blood-brain barrier (BBB) precludes access of systemically administered medicines to brain tissue. Consequently, there is a need for drug delivery vehicles that mediate transendothelial transport of such medicines. Endothelial cells use a variety of endocytotic pathways for the internalization of exogenous materials, including clathrin-mediated endocytosis, caveolar endocytosis, and macropinocytosis. The different modes of endocytosis result in the delivery of endocytosed material to distinctive intracellular compartments and therewith correlated differential processing. To obtain insight into the properties of drug delivery vehicles that direct their intracellular processing in brain endothelial cells, we investigated the intracellular processing of fixed-size nanoparticles in an in vitro BBB model as a function of distinct nanoparticle surface modifications. Caveolar endocytosis, adsorptive-mediated endocytosis, and receptor-mediated endocytosis were promoted by the use of uncoated 500-nm particles, attachment of the cationic polymer polyethyleneimine (PEI), and attachment of prion proteins, respectively. We demonstrate that surface modifications of nanoparticles, including charge and protein ligands, affect their mode of internalization by brain endothelial cells and thereby their subcellular fate and transcytotic potential.

Citing Articles

Brain neurons internalise polymeric micron-sized capsules: Insights from and studies.

Kopach O, Sindeeva O, Zheng K, McGowan E, Sukhorukov G, Rusakov D Mater Today Bio. 2025; 31:101493.

PMID: 39944534 PMC: 11815287. DOI: 10.1016/j.mtbio.2025.101493.


Advancing CNS Therapeutics: Enhancing Neurological Disorders with Nanoparticle-Based Gene and Enzyme Replacement Therapies.

Liu S, Li H, Xi S, Zhang Y, Sun T Int J Nanomedicine. 2025; 20:1443-1490.

PMID: 39925682 PMC: 11806685. DOI: 10.2147/IJN.S457393.


Breaking free: endocytosis and endosomal escape of extracellular vesicles.

Ribovski L, Joshi B, Gao J, Zuhorn I Extracell Vesicles Circ Nucl Acids. 2024; 4(2):283-305.

PMID: 39697985 PMC: 11648447. DOI: 10.20517/evcna.2023.26.


cRGD-Peptide Modified Covalent Organic Frameworks for Precision Chemotherapy in Triple-Negative Breast Cancer.

Benyettou F, Khair M, Prakasam T, Varghese S, Matouk Z, Alkaabi M ACS Appl Mater Interfaces. 2024; 16(42):56676-56695.

PMID: 39267454 PMC: 11503616. DOI: 10.1021/acsami.4c10812.


Chitosan-Tricarbocyanine-Based Nanogels Were Able to Cross the Blood-Brain Barrier Showing Its Potential as a Targeted Site Delivery Agent.

Rivera Lopez E, Samaniego Lopez C, Spagnuolo C, Berardino B, Alaimo A, Perez O Pharmaceutics. 2024; 16(7).

PMID: 39065661 PMC: 11280413. DOI: 10.3390/pharmaceutics16070964.


References
1.
Weksler B, Subileau E, Perriere N, Charneau P, Holloway K, Leveque M . Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005; 19(13):1872-4. DOI: 10.1096/fj.04-3458fje. View

2.
Doherty G, McMahon H . Mechanisms of endocytosis. Annu Rev Biochem. 2009; 78:857-902. DOI: 10.1146/annurev.biochem.78.081307.110540. View

3.
Pardridge W, Buciak J, Friden P . Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther. 1991; 259(1):66-70. View

4.
Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S . Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release. 2009; 137(1):78-86. DOI: 10.1016/j.jconrel.2009.03.002. View

5.
Shurety W, Stewart N, Stow J . Fluid-phase markers in the basolateral endocytic pathway accumulate in response to the actin assembly-promoting drug Jasplakinolide. Mol Biol Cell. 1998; 9(4):957-75. PMC: 25321. DOI: 10.1091/mbc.9.4.957. View